Opinions
Norman Levine
EssilorLuxottica
ESLOY-OTC
PAST TOP PICK
Jan 14, 2022
(A Top Pick May 07/21, Up 14%) Believes company is in process of optimization previous mergers.
Covid-19 pandemic has had adverse affect on company, which created a good buying opportunity.
As economy re-opens the company will do well.
Continues to own the stock.
$98.230
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
price target N/A The global leader in optical frames, lens and sunglasses. The eyewear business is long-term resilient and will grow. A great demographic play, too. Over the last two years, screen use has soared and has caused a lot of eye problems. They bought Grand Vision, which is transformational in a digital way. Pays a 2.3X dividend. Strong balance sheet and cash flow growth will rise.
Healthcare
PAST TOP PICK
(A Top Pick Aug 24/21, Down 19%) It is a leader in the design, manufacturing and distribution of lenses, frames and sunglasses. Has a great balance sheet and should have good growth for the next few years. It acquired Grand Vision, mostly European, which changed the dynamics of the company and helps them to have a broader digital component. Has a 2.3% dividend.
Healthcare
TOP PICK
Lenses plus frames. Has a lock on the whole value chain. Purchase of Grant Vision will dramatically change its business over the next several years. Use of lenses has increased because of aging demographics plus faster eye deterioration from computer screens. Also a fashion statement. Great technology. Yield is 1.7%.
(Analysts’ price target is $109.40)
Healthcare
Advertising